title: Expression of androgen receptor is negatively regulated by p53.
abstract: Increased expression of androgen receptor (AR) in prostate cancer (PC) is associated with transition to androgen independence. Because the progression of PC to advanced stages is often associated with the loss of p53 function, we tested whether the p53 could regulate the expression of AR gene. Here we report that p53 negatively regulates the expression of AR in prostate epithelial cells (PrECs). We found that in LNCaP human prostate cancer cells that express the wild-type p53 and AR and in human normal PrECs, the activation of p53 by genotoxic stress or by inhibition of p53 nuclear export downregulated the expression of AR. Furthermore, forced expression of p53 in LNCaP cells decreased the expression of AR. Conversely, knockdown of p53 expression in LNCaP cells increased the AR expression. Consistent with the negative regulation of AR expression by p53, the p53-null HCT116 cells expressed higher levels of AR compared with the isogenic HCT116 cells that express the wildtype p53. Moreover, we noted that in etoposide treated LNCaP cells p53 bound to the promoter region of the AR gene, which contains a potential p53 DNA-binding consensus sequence, in chromatin immunoprecipitation assays. Together, our observations provide support for the idea that the loss of p53 function in prostate cancer cells contributes to increased expression of AR.
authors: Edward Hines Jr. VA Hospital, Hines, IL 60141, USA.
authors: Fatouma
authors: F
authors: Alimirah
authors: Ravichandran
authors: R
authors: Panchanathan
authors: Jianming
authors: J
authors: Chen
authors: Xiang
authors: X
authors: Zhang
authors: Shuk-Mei
authors: SM
authors: Ho
authors: Divaker
authors: D
authors: Choubey
mesh_terms: D020121:5' Untranslated Regions / Q000235:genetics; D000230:Adenocarcinoma / Q000235:genetics / Q000473:pathology*; D000728:Androgens; D001859:Bone Neoplasms / Q000235:genetics / Q000473:pathology; D045744:Cell Line, Tumor / Q000187:drug effects / Q000378:metabolism; D015179:Colorectal Neoplasms / Q000235:genetics / Q000473:pathology; D016384:Consensus Sequence; D004273:DNA, Neoplasm / Q000235:genetics; D005047:Etoposide / Q000494:pharmacology; D015972:Gene Expression Regulation, Neoplastic; D016158:Genes, p53; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000235:genetics / Q000473:pathology*; D012516:Osteosarcoma / Q000235:genetics / Q000473:pathology; D011401:Promoter Regions, Genetic; D011471:Prostatic Neoplasms / Q000235:genetics / Q000473:pathology*; D034741:RNA, Small Interfering / Q000235:genetics; D011944:Receptors, Androgen / Q000096:biosynthesis* / Q000235:genetics; D014162:Transfection; D016159:Tumor Suppressor Protein p53 / Q000172:deficiency / Q000502:physiology*
chemical_list: D020121:5' Untranslated Regions; C410798:AR protein, human; D000728:Androgens; D004273:DNA, Neoplasm; D034741:RNA, Small Interfering; D011944:Receptors, Androgen; D016159:Tumor Suppressor Protein p53; D005047:Etoposide